Pemetrexed
is a chemotherapy drug indicated for the treatment of pleural
mesothelioma and non-small cell lung cancer. Pemetrexed is a patented
drug of Eli Lilly and Company and sold under brand name Alimta. In
2004, Alimta (Pemetrexed injection) was approved by FDA in
combination with cisplatin as an initial treatment for patients with
malignant pleural mesothelioma. In 2008, ALIMTA, in combination with
cisplatin, was approved as an initial chemotherapy treatment for
locally advanced or metastatic NSCLC for patients with nonsquamous
histology, and in 2009, ALIMTA was approved as a maintenance therapy
for locally advanced or metastatic nonsquamous non-small cell lung
cancer (NSCLC).
Request
PDF Brochure of Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2458
Market
Dynamics
Launch
of generic version of pemetrexed in key region is expected to
increase affordability of pemetrexed, which in turn is expected to
support global pemetrexed market growth over the forecast period.
For
instance, in July 2018, STADAPHARM GmbH, the subsidiary of STADA
Arzneimittel AG launched Pemetrexed STADA generic version of Alimta
in Europe.
High
prevalence of non-small cell lung cancer and pleural mesothelioma is
expected to rise the demand for Pemetrexed for its treatment and
support global pemetrexed market growth over the forecast period.
For
instance, according to the data published by American Society of
Clinical Oncology, in January 2018, in the U.S. around 234,030 adults
(121,680 men and 112,350 women) were diagnosed with lung cancer among
which non-small cell lung cancer is the most common type of lung
cancer, accounting for 80% to 85% of all lung cancer diagnose.
North
America is expected to Hold Dominant Position, Owing to High
Prevalence of Non-small Cell Lung Cancer and its High Treatment Rate
in the U.S.
According
to Eli Lilly and Company’s annual report 2017, Alimta (pemetrexed)
generated around 50% of its revenue from the U.S. Hence, North
America is expected to be most conducive region for growth of the
pemetrexed market, due to high prevalence of non-small cell lung
cancer and high cost for its treatment.
For
instance, according to the data published by the American Cancer
Society in 2017, lung cancer (both small cell and non-small cell) is
the second most common type of cancer in U.S and around 13% of all
new cancers are lung cancer.
American
Cancer Society also estimated that in 2019, around 228,150 new cases
of lung cancer (116,440 in men and 111,710 in women) would be
diagnosed in the U.S. and survival rate for non-small cell lung
cancer in stage IA1 NSCLC is about 92%, stage IB NSCLC (68%), stage
IIIA NSCLC (36%), stage IIIC cancers (13%), and for stage IIIC
cancers (13%).
Key
players operating in the global pemetrexed market include Eli Lilly
and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., and
others.
Detailed
Segmentation:
Global
Pemetrexed Market, By Strength :
-
100 mg
-
500 mg
Global
Pemetrexed Market, By Distribution Channel:
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
Get
Full Access of This Business Report:
https://www.coherentmarketinsights.com/market-insight/pemetrexed-market-2458
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment